Wealthstreet Investment Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Wealthstreet Investment Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-14,770	Closed	-$1.1M	–	291
2021 Q1	$1.1M	Sell	14,770 -1,605	-10%	-$148K	0.11%	162
2020 Q4	$2.79M	Sell	16,375 -1,500	-8%	-$222K	0.28%	80
2020 Q3	$2.51M	Sell	17,875 -300	-2%	-$45.6K	0.28%	82
2020 Q2	$2.91M	Hold	18,175	–	–	0.36%	66
2020 Q1	$1.78M	Buy	18,175 +5,145	+39%	+$588K	0.26%	91
2019 Q4	$1.68M	Buy	13,030 +110	+0.9%	+$11.1K	0.2%	112
2019 Q3	$1.12M	Buy	12,920 +5,200	+67%	+$614K	0.14%	129
2019 Q2	$1.17M	Buy	7,720 +1,200	+18%	+$146K	0.15%	132
2019 Q1	$777K	Buy	6,520 +3,890	+148%	+$500K	0.1%	169
2018 Q4	$305K	Buy	+2,630	New	+$329K	0.04%	268

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Wealthstreet Investment Advisors's SRPT Position: Q2 2021 in Review

Wealthstreet Investment Advisors sold out of Sarepta Therapeutics (SRPT) in Q2 2021, closing a stake of 14,770 shares — an estimated $1.1M sold.

Wealthstreet Investment Advisors first reported a position in SRPT in Q4 2018 and held it in 10 quarters. The position peaked at $2.91M in Q2 2020. 331 funds tracked by Wall St. Rank hold SRPT as of Q2 2021.

Wealthstreet Investment Advisors reported no remaining Sarepta Therapeutics position as of Q2 2021 after selling out during the quarter.
Wealthstreet Investment Advisors sold 14,770 Sarepta Therapeutics shares in Q2 2021, an estimated $1.1M.
Wealthstreet Investment Advisors first reported a position in Sarepta Therapeutics in Q4 2018 and held it in 10 quarters.
Wealthstreet Investment Advisors's Sarepta Therapeutics position peaked at $2.91M in Q2 2020.
331 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2021.

Based on Wealthstreet Investment Advisors's 13F filing for Q2 2021, filed 2 Aug 2021.